Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation

BackgroundThe administration of modified immune cells (MIC) before kidney transplantation led to specific immunosuppression against the allogeneic donor and a significant increase in regulatory B lymphocytes. We wondered how this approach affected the continued clinical course of these patients.Meth...

Full description

Bibliographic Details
Main Authors: Matthias Schaier, Christian Morath, Lei Wang, Christian Kleist, Gerhard Opelz, Thuong Hien Tran, Sabine Scherer, Lien Pham, Naruemol Ekpoom, Caner Süsal, Gerald Ponath, Florian Kälble, Claudius Speer, Louise Benning, Christian Nusshag, Christoph F. Mahler, Luiza Pego da Silva, Claudia Sommerer, Angela Hückelhoven-Krauss, David Czock, Arianeb Mehrabi, Constantin Schwab, Rüdiger Waldherr, Paul Schnitzler, Uta Merle, Vedat Schwenger, Markus Krautter, Stephan Kemmner, Michael Fischereder, Manfred Stangl, Ingeborg A. Hauser, Anna-Isabelle Kälsch, Bernhard K. Krämer, Georg A. Böhmig, Carsten Müller-Tidow, Jochen Reiser, Martin Zeier, Michael Schmitt, Peter Terness, Anita Schmitt, Volker Daniel
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
transplantation - kidney
tolerance
cell therapy
regulatory B (Breg) cells
phase I (drug development)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1089664/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1089664/full

Similar Items